(Reuters) - Bio-Rad Laboratories on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro challenges, sending the company's ...
BIO-RAD LABORATORIES ($BIO) posted quarterly earnings results on Thursday, February 13th. The company reported earnings of $2.90 per share, beating estimates of $2.90 ...
PLEASANTON — Bio-Rad Laboratories, setting the stage for a big expansion in the East Bay, has bought a two-building complex in Pleasanton’s Hacienda Business Park to accommodate plans for more workers ...
(Reuters) - Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients. Shares of the diagnostics ...
Hosted on MSN
Bio-Rad targets 1.5%-3.5% revenue growth in 2025 amid operational improvements and new acquisitions
Earnings Call Insights: Bio-Rad Laboratories (NYSE:BIO) Q4 2024 Chief Operating Officer Jon DiVincenzo stated that Bio-Rad met its revised 2024 guidance for revenue and operating margin, achieving ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its Real-Time qPCR ...
RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report) on October 23 and set a price target of $446.00. The company’s shares closed yesterday at ...
Bio-Rad Labs B’s stock price closed at $338.75. It is up 37.22% in the last 3 months and down -5.43% in the last 12 months. Bio-Rad Labs B saw positive EPS revisions and negative EPS revisions in the ...
Bio-Rad Labs (NYSE:BIO): Q4 Non-GAAP EPS of $4.01 beats by $0.69; GAAP EPS of $27.81. Revenue of $789.8M (+26.5% Y/Y) beats by $100.37M. Press Release Recommended For You ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback